Aspire Biopharma Holdings, Inc. (ASBP)

US — Healthcare Sector
Peers:

Automate Your Wheel Strategy on ASBP

With Tiblio's Option Bot, you can configure your own wheel strategy including ASBP - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol ASBP
  • Rev/Share 0.0
  • Book/Share -0.1983
  • PB -1.6029
  • Debt/Equity -0.8226
  • CurrentRatio 0.0877
  • ROIC 1.8423

 

  • MktCap 15744306.0
  • FreeCF/Share -0.0292
  • PFCF -69.3799
  • PE -0.1979
  • Debt/Assets 8.5603
  • DivYield 0
  • ROE -3.1836

 

  • Rating C
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 1
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

Aspire Biopharma Holdings, Inc., Announces Institutional Review Board Approval for In-Human Clinical Trial of an Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation
ASBP
Published: April 29, 2025 by: Accesswire
Sentiment: Neutral

Company achieves another milestone relating to its clinical trial strategy HUMACAO, PR and NEW YORK, NY / ACCESS Newswire / April 29, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), a developer of a multi-faceted patent-pending drug delivery technology, today announced that it has received Institutional Review Board (IRB) approval of the clinical trial protocol for its upcoming Phase I single-center clinical trial in the United States designed to evaluate safety, pharmacokinetics and pharmacodynamics, of its lead therapeutic candidate, an oral transmucosal fast-acting high-dose aspirin formulation. One clinical trial site has been activated with patient enrollment expected …

Read More
image for news Aspire Biopharma Holdings, Inc., Announces Institutional Review Board Approval for In-Human Clinical Trial of an Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation

About Aspire Biopharma Holdings, Inc. (ASBP)

  • IPO Date 2022-04-11
  • Website https://aspirebiolabs.com/
  • Industry Biotechnology
  • CEO Mr. Kraig T. Higginson
  • Employees 2
Aspire Biopharma Holdings, Inc. is a biotechnology company specializing in advanced diagnostic solutions and molecular testing. The company focuses on developing high-precision assays for disease detection, leveraging cutting-edge research in genetics and biochemistry to support healthcare and life sciences industries.